Do analysts rate PPCB or LNAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PPCB or LNAI more profitable?

Propanc Biopharma's return on equity of -151.28% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Propanc Biopharma N/A -151.28% -109.53% Lunai Bioworks N/A -1,243.45% -1,617.76%

Does the media prefer PPCB or LNAI?

In the previous week, Propanc Biopharma had 2 more articles in the media than Lunai Bioworks. MarketBeat recorded 3 mentions for Propanc Biopharma and 1 mentions for Lunai Bioworks. Propanc Biopharma's average media sentiment score of 0.86 beat Lunai Bioworks' score of 0.67 indicating that Propanc Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Propanc Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lunai Bioworks 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate COCP or PPCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, COCP or PPCB?

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cocrystal Pharma N/A N/A -$8.83M -$0.73 N/A Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A

Is COCP or PPCB more profitable?

Cocrystal Pharma's return on equity of -150.61% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -150.61% -97.86% Propanc Biopharma N/A -151.28% -109.53%

Do analysts recommend HOOK or PPCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HOOKIPA Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer PPCB or QNTM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, PPCB or QNTM?

Quantum Biopharma is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A Quantum Biopharma N/A N/A -$26.17M -$8.25 N/A

Is PPCB or QNTM more profitable?

Propanc Biopharma's return on equity of -151.28% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Propanc Biopharma N/A -151.28% -109.53% Quantum Biopharma N/A -941.54% -224.41%

Does the media prefer PPCB or QNTM?

In the previous week, Quantum Biopharma had 1 more articles in the media than Propanc Biopharma. MarketBeat recorded 4 mentions for Quantum Biopharma and 3 mentions for Propanc Biopharma. Propanc Biopharma's average media sentiment score of 0.86 beat Quantum Biopharma's score of 0.24 indicating that Propanc Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Propanc Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quantum Biopharma 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate GRTX or PPCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, GRTX or PPCB?

Propanc Biopharma is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galera Therapeutics N/A N/A -$59.08M $0.64 0.14 Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A

Is GRTX or PPCB more profitable?

Galera Therapeutics' return on equity of 0.00% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Galera Therapeutics N/A N/A -99.34% Propanc Biopharma N/A -151.28% -109.53%

Propanc Biopharma (PPCB) Competitors

$1.77 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$1.69 -0.08 (-4.75%)

As of 07/2/2026 07:59 PM Eastern

Compare

PPCB vs. LNAI, COCP, HOOK, QNTM, and GRTX

Should you buy Propanc Biopharma stock or one of its competitors? MarketBeat compares Propanc Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Propanc Biopharma include Lunai Bioworks (LNAI), Cocrystal Pharma (COCP), HOOKIPA Pharma (HOOK), Quantum Biopharma (QNTM), and Galera Therapeutics (GRTX). These companies are all part of the "pharmaceutical products" industry.

How does Propanc Biopharma compare to Lunai Bioworks?

Propanc Biopharma (NASDAQ:PPCB) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Propanc Biopharma has a beta of 3.49, indicating that its share price is 249% more volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market.

Propanc Biopharma's return on equity of -151.28% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%

Propanc Biopharma has higher earnings, but lower revenue than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
Lunai Bioworks	$20.94K	692.81	-$178.01M	-$0.40	N/A

71.4% of Lunai Bioworks shares are held by institutional investors. 28.5% of Propanc Biopharma shares are held by company insiders. Comparatively, 0.5% of Lunai Bioworks shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Propanc Biopharma had 2 more articles in the media than Lunai Bioworks. MarketBeat recorded 3 mentions for Propanc Biopharma and 1 mentions for Lunai Bioworks. Propanc Biopharma's average media sentiment score of 0.86 beat Lunai Bioworks' score of 0.67 indicating that Propanc Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Propanc Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lunai Bioworks	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Propanc Biopharma beats Lunai Bioworks on 8 of the 11 factors compared between the two stocks.

How does Propanc Biopharma compare to Cocrystal Pharma?

Cocrystal Pharma (NASDAQ:COCP) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

In the previous week, Propanc Biopharma had 3 more articles in the media than Cocrystal Pharma. MarketBeat recorded 3 mentions for Propanc Biopharma and 0 mentions for Cocrystal Pharma. Propanc Biopharma's average media sentiment score of 0.86 beat Cocrystal Pharma's score of 0.00 indicating that Propanc Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
Propanc Biopharma	Positive

6.7% of Cocrystal Pharma shares are held by institutional investors. 39.4% of Cocrystal Pharma shares are held by insiders. Comparatively, 28.5% of Propanc Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cocrystal Pharma has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.49, indicating that its stock price is 249% more volatile than the broader market.

Cocrystal Pharma's return on equity of -150.61% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
Propanc Biopharma	N/A	-151.28%	-109.53%

Summary

Cocrystal Pharma beats Propanc Biopharma on 6 of the 10 factors compared between the two stocks.

How does Propanc Biopharma compare to HOOKIPA Pharma?

HOOKIPA Pharma (NASDAQ:HOOK) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

Propanc Biopharma has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. HOOKIPA Pharma's return on equity of -120.09% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HOOKIPA Pharma	-785.66%	-120.09%	-77.14%
Propanc Biopharma	N/A	-151.28%	-109.53%

HOOKIPA Pharma has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.49, indicating that its share price is 249% more volatile than the broader market.

HOOKIPA Pharma has higher revenue and earnings than Propanc Biopharma. HOOKIPA Pharma is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HOOKIPA Pharma	$9.35M	1.52	-$43.50M	-$3.54	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

In the previous week, Propanc Biopharma had 3 more articles in the media than HOOKIPA Pharma. MarketBeat recorded 3 mentions for Propanc Biopharma and 0 mentions for HOOKIPA Pharma. Propanc Biopharma's average media sentiment score of 0.86 beat HOOKIPA Pharma's score of 0.00 indicating that Propanc Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
HOOKIPA Pharma	Neutral
Propanc Biopharma	Positive

63.9% of HOOKIPA Pharma shares are owned by institutional investors. 3.3% of HOOKIPA Pharma shares are owned by insiders. Comparatively, 28.5% of Propanc Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HOOKIPA Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Propanc Biopharma beats HOOKIPA Pharma on 7 of the 13 factors compared between the two stocks.

How does Propanc Biopharma compare to Quantum Biopharma?

Propanc Biopharma (NASDAQ:PPCB) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

1.2% of Quantum Biopharma shares are owned by institutional investors. 28.5% of Propanc Biopharma shares are owned by insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Propanc Biopharma's return on equity of -151.28% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
Quantum Biopharma	N/A	-941.54%	-224.41%

Quantum Biopharma is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

Propanc Biopharma has a beta of 3.49, suggesting that its stock price is 249% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

In the previous week, Quantum Biopharma had 1 more articles in the media than Propanc Biopharma. MarketBeat recorded 4 mentions for Quantum Biopharma and 3 mentions for Propanc Biopharma. Propanc Biopharma's average media sentiment score of 0.86 beat Quantum Biopharma's score of 0.24 indicating that Propanc Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Propanc Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quantum Biopharma	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Propanc Biopharma beats Quantum Biopharma on 6 of the 10 factors compared between the two stocks.

How does Propanc Biopharma compare to Galera Therapeutics?

Galera Therapeutics (NASDAQ:GRTX) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Galera Therapeutics has a beta of 2.6, indicating that its stock price is 160% more volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.49, indicating that its stock price is 249% more volatile than the broader market.

Propanc Biopharma is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.14
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

Galera Therapeutics' return on equity of 0.00% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galera Therapeutics	N/A	N/A	-99.34%
Propanc Biopharma	N/A	-151.28%	-109.53%

50.8% of Galera Therapeutics shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by insiders. Comparatively, 28.5% of Propanc Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Propanc Biopharma had 3 more articles in the media than Galera Therapeutics. MarketBeat recorded 3 mentions for Propanc Biopharma and 0 mentions for Galera Therapeutics. Propanc Biopharma's average media sentiment score of 0.86 beat Galera Therapeutics' score of 0.00 indicating that Propanc Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Galera Therapeutics	Neutral
Propanc Biopharma	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Propanc Biopharma beats Galera Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Propanc Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PPCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PPCB vs. The Competition

Export

Metric	Propanc Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.03M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-0.07	21.61	28.02	24.70
Price / Sales	N/A	340.22	540.55	99.42
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	0.06	8.66	10.96	6.46
Net Income	-$58.92M	$23.81M	$3.57B	$337.01M
7 Day Performance	20.41%	3.39%	2.12%	1.69%
1 Month Performance	22.07%	10.81%	5.25%	3.81%
1 Year Performance	-98.33%	62.61%	33.29%	23.90%

Propanc Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PPCB Propanc Biopharma	0.7979 of 5 stars	$1.77 flat	N/A	-98.3%	$4.03M	N/A	N/A	1	News Coverage Buyback Announcement Gap Up High Trading Volume
LNAI Lunai Bioworks	0.494 of 5 stars	$3.17 -1.2%	N/A	N/A	$14.37M	$20.94K	N/A	20	News Coverage Gap Down
COCP Cocrystal Pharma	0.3221 of 5 stars	$1.03 +1.0%	N/A	-32.5%	$14.20M	N/A	N/A	10
HOOK HOOKIPA Pharma	N/A	$1.15 flat	N/A	-9.1%	$14.18M	$9.35M	N/A	160	Gap Down
QNTM Quantum Biopharma	0.6685 of 5 stars	$3.70 -2.6%	N/A	-79.5%	$14.13M	N/A	N/A	N/A	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PPCB) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Propanc Biopharma (PPCB) Competitors

PPCB vs. LNAI, COCP, HOOK, QNTM, and GRTX

How does Propanc Biopharma compare to Lunai Bioworks?

Summary

How does Propanc Biopharma compare to Cocrystal Pharma?

Summary

How does Propanc Biopharma compare to HOOKIPA Pharma?

Summary

How does Propanc Biopharma compare to Quantum Biopharma?

Summary

How does Propanc Biopharma compare to Galera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPCB vs. The Competition

Propanc Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Propanc Biopharma (PPCB) Competitors

PPCB vs. LNAI, COCP, HOOK, QNTM, and GRTX

How does Propanc Biopharma compare to Lunai Bioworks?

Do analysts rate PPCB or LNAI?

Which has more volatility and risk, PPCB or LNAI?

Is PPCB or LNAI more profitable?

Which has stronger valuation & earnings, PPCB or LNAI?

Do insiders and institutionals hold more shares of PPCB or LNAI?

Does the media prefer PPCB or LNAI?

Summary

How does Propanc Biopharma compare to Cocrystal Pharma?

Which has preferable valuation and earnings, COCP or PPCB?

Does the media favor COCP or PPCB?

Do insiders & institutionals believe in COCP or PPCB?

Do analysts rate COCP or PPCB?

Which has more risk and volatility, COCP or PPCB?

Is COCP or PPCB more profitable?

Summary

How does Propanc Biopharma compare to HOOKIPA Pharma?

Is HOOK or PPCB more profitable?

Which has more risk & volatility, HOOK or PPCB?

Which has better earnings and valuation, HOOK or PPCB?

Does the media refer more to HOOK or PPCB?

Do institutionals & insiders have more ownership in HOOK or PPCB?

Do analysts recommend HOOK or PPCB?

Summary

How does Propanc Biopharma compare to Quantum Biopharma?

Do institutionals & insiders believe in PPCB or QNTM?

Do analysts prefer PPCB or QNTM?

Is PPCB or QNTM more profitable?

Which has preferable valuation and earnings, PPCB or QNTM?

Which has more risk & volatility, PPCB or QNTM?

Does the media prefer PPCB or QNTM?

Summary

How does Propanc Biopharma compare to Galera Therapeutics?

Which has more risk & volatility, GRTX or PPCB?

Which has higher valuation & earnings, GRTX or PPCB?

Is GRTX or PPCB more profitable?

Do insiders and institutionals hold more shares of GRTX or PPCB?

Does the media favor GRTX or PPCB?

Do analysts rate GRTX or PPCB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPCB vs. The Competition

Propanc Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools